News Releases

News Releases

Nov 11, 2021
PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 11, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare
Nov 01, 2021
Program to Highlight UGN-102 and Company’s Innovative Early-stage Pipeline Programs Company to Report Third Quarter 2021 Financial Results on November 15, 2021 PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 1, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and
Oct 05, 2021
Clinically Meaningful Response and Sustained Durability Underscore Potential for UGN-102 to Become a Non-Surgical Primary Therapeutic Treatment for Patients with Highly Recurrent LG IR-NMIBC 65% Complete Response (CR) Rate at Three Months 61% of Patients Remain in CR at 12 Months Data Supports